Lexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) EV/Sales
As of 16 October 2026, Lexicon Pharmaceuticals, Inc. (LXRX) trades at a EV/Sales of 12.8×. Over the past ten years it has ranged from −1.4× (March 2025) to 4,793× (May 2023); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | 133.15% |
| FY2024 | 3.2× | (98.62%) |
| FY2023 | 235× | (86.49%) |
| FY2022 | 1,736× | 5.71% |
| FY2021 | 1,642× | 16,384.30% |
| FY2020 | 10.0× | 674.47% |
| FY2019 | 1.3× | (89.68%) |
| FY2018 | 12.5× | 14.27% |
| FY2017 | 10.9× | (29.72%) |
| FY2016 | 15.5× | 110.06% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 22.1× | 202.75% |
| Mar 2026 | 7.3× | (3.20%) |
| Dec 2025 | 7.5× | 12.85% |
| Sep 2025 | 6.7× | 28.23% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVA Inventiva S.A. Sponsored ADR compare | −0.1× |
| SANA Sana Biotechnology, Inc. compare | n/m |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.6× |
| LXRX Lexicon Pharmaceuticals, Inc. | 12.8× |
| OABI OmniAb, Inc. compare | 14.0× |
| ACHV Achieve Life Sciences, Inc. compare | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)